PharmEasy, an online medicine delivery startup, agreed to acquire a 66.14% stake in Thyrocare Technologies, a chain of diagnostic and preventive care laboratories, for $614m. The acquisition has triggered an open offer under which PharmEasy will acquire up to 26% shareholding in the company from public shareholders.